Asthma in infants and children—Treatment of childhood asthma: Part II

Rachelefsky, Gary S.; Siegel, Sheldon C.

doi:10.1016/0091-6749(85)90718-3

Cited by 23 publications

(4 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, serum levels in excess of 120 p g/ml have been reported in acute intoxication without significant side effects (Rachelefsky and Siegel 1985). The lack of side effects has been attributed to the acute elevation.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, Jones (1986) reported two cases with bronchial asthma whose conditions were well controlled without significant side effects despite the higher serum concentrations of theophylline ranging from 25-35 p g/ml. On the other hand, in children, the lower concentrations of theophylline are recommended, depending upon the individual response (Rachelefsky and Siegel 1985).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Permanent brain damage possibly caused by theophylline in two elderly patients with airway obstruction.

Sekizawa

Aikawa

Yanai

et al. 1990

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Permanent brain damage possibly caused by theophylline in two elderly patients with airway obstruction.

Sekizawa

Aikawa

Yanai

et al. 1990

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…As result, it is widely used for the treatment of asthma in adults (3) and children (4). Since the half-life of orally administered salbutamol is approximately 5 h, the drug must be dosed 3-4 times daily to maintain bronchodilation.…”

Section: Introductionmentioning

confidence: 99%

Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol

Hernández¹,

Rodríguez-Gascón²,

Calvo³

et al. 1997

European Journal of Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

The present study was carried out to define the pharmacokinetics of salbutamol sulfate administered to mongrel dogs in five pharmaceutical forms via two routes of administration. One pharmaceutical form was administered intravenously (Ventolin i.v.) while the other four were administered orally (Ventolin: immediate-release formulation, Volmax: commercial osmotic pump, SG7 and SG14: sustained-release hydrophilic matrices developed in our laboratory). We obtained a first-order release kinetic of the salbutamol from Ventolin and SG7, whereas a zero-order release kinetic was observed for SG14 and Volmax formulations. Oral bioavailability was 80% and there were neither significant differences (P > 0.05) in terms of the calculation method used (relation of the areas under the plasma level curve Loo-Riegelman, deconvolution) nor in terms of the dosage form (Ventolin Volmax, SG7 and SG14). The elimination half-life value of salbutamol was 1.2 h when administered intravenously; this parameter had a value of 3.0 h for the immediate-release formulation and ranged between 5.4 and 7.2 h in the sustained-release formulations when administered orally. These changes in the half-life value of the sustained-release formulations will allow us to modify the frequency of administration in relation to immediate-release formulations.

show abstract

“…A single treatment with three sprays of bitolterol,'2' and repetitive dosing for 6 weeks with three sprays San Diego, CA, Seattle, WA, Murray, UT, Durham, NC, Madison, WI, Prairie Village, KS, Denver, CO, Hartford, CT, Rensselaer, NY, Colorado Springs, CO, Atlanta, GA. tid,'3' for 3 months with three sprays tid,'4' and for 3 months with two sprays tid'5' have demonstrated bronchodilation for 4 to more than 8 hours. A single treatment, dose-response study in children aged [4][5][6][7][8][9][10][11][12] years old who received one, two, or three sprays of bitolterol by metered-dose inhaler (MDI) revealed that the response was generally dose related, with the maximum effect after three inhalations. The mean duration of bronchodilation was 4 hours, although it persisted in some children for more than 8 hours.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Bitolterol Mesylate and Isoproterenol by Metered-Dose Inhaler for Regular, Long-Term Treatment in Asthmatic Children

Welch¹,

Kemp²,

Bierman³

et al. 1989

Pediatric Asthma, Allergy & Immunology

View full text Add to dashboard Cite

The objective of this study was to compare the efficacy and safety of bitolterol mesylate and isoproterenol hydrochloride, two sprays by metered-dose inhaler three times a day for 3 months in 240 asthmatic children ages 4-12 years. In this double-blind, randomized, parallel, multicenter study, patients received daily bitolterol mesylate or isoproterenol and were evaluated in the office at the beginning of the study and on 3 additional test days at 1-month intervals. They were evaluated by physical exam and ECG, blood and urine analyses, and spirometry for 8 hours after two sprays of the appropriate study aerosol. Theophylline was withheld for 24 hours and the study drug for 12 hours before office study days. All regular asthma medications were continued together with the bitolterol mesylate or isoproterenol between study days. Bronchodilation >15% above baseline occurred in <5 minutes with both treatments. Median durations of action were 3.1-4.4 and 1.2-2.2 hours with bitolterol mesylate and isoproterenol, respectively. Adverse effects were few and did not differ between drugs.

show abstract

Asthma in infants and children—Treatment of childhood asthma: Part II

Cited by 23 publications

References 71 publications

Permanent brain damage possibly caused by theophylline in two elderly patients with airway obstruction.

Permanent brain damage possibly caused by theophylline in two elderly patients with airway obstruction.

Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol

Comparison of Bitolterol Mesylate and Isoproterenol by Metered-Dose Inhaler for Regular, Long-Term Treatment in Asthmatic Children

Contact Info

Product

Resources

About